Methods of treating developmental disorders with gaboxadol

Abstract

Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X—associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.

What is claimed is: 
     
         1 . A composition comprising a compound according to formula I: 
       
         
           
           
               
               
           
         
         wherein the compound is provided in a pharmaceutical formulation for the treatment of a developmental disorder. 
       
     
     
         2 . The compound of  claim 1 , wherein the pharmaceutical formulation comprises about 1 mg to about 30 mg gaboxadol or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The compound of  claim 1 , wherein the pharmaceutical formulation comprises about 1 mg to about 25 mg gaboxadol or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The compound of  claim 1 , wherein the pharmaceutical formulation comprises about 1 mg to about 15 mg gaboxadol or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The compound of  claim 1 , wherein the pharmaceutical formulation comprises about 1 mg to about 10 mg gaboxadol or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The compound of  claim 1 , wherein the pharmaceutical formulation provides an in vivo plasma profile of a patient 6 hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof that is reduced by more than 50%. 
     
     
         7 . The compound of  claim 1 , wherein the developmental disorder is selected from the group consisting of an Autistic Spectrum Disorder, Autism, Angelman syndrome, and Fragile X syndrome. 
     
     
         8 . The compound of  claim 1 , wherein the developmental disorder is an Autistic Spectrum Disorder. 
     
     
         9 . The compound of  claim 1 , wherein the developmental disorder is Autism. 
     
     
         10 . The compound of  claim 1 , wherein the developmental disorder is Angelman syndrome. 
     
     
         11 . The compound of  claim 1 , wherein the developmental disorder is Fragile X syndrome.